-
-
Abemaciclib
-
Afamelanotide
-
Alicaforsen
-
Asfotase alfa
-
Atezolizumab
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Blaaskanker
- NSCLC, 2e behandeling
- Indication couldn't be found
- Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
-
Avelumab
-
Blinatumomab
-
Botulinum A toxin
- Chronic sialorrhoea in adults and children, associated with neurological conditions (Parkinson’s Disease (PD), stroke, traumatic brain injury (TBI), cerebral palsy (CP) (licence extension)
- Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI) (licence extension)
- Lower limb spasticity (LLS), post stroke (licence extension).
-
CTL019
-
Canakinumab
-
Cholic acid
-
Dupilumab
-
Durvalumab
- Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L monotherapy in PDL1-positive tumours or in combination with tremelimumab for PDL1-negative tumours.
- Non-small cell lung cancer (NSCLC) stage 4, PD-L1+, 1L
- Locally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum‑based regimen
-
Empagliflozin
-
Empagliflozin / linagliptin
-
Ibrutinib
-
Ipilimumab
-
Leuco-methylthioninium
-
Masitinib
-
Migalastat
-
Nivolumab
- Huidkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
-
Nivolumab
-
Obeticholic acid
-
Olaparib
- Breast cancer (HER2+, BCRA mutated; adjuv.)
- Tabletten ipv capsules voor onderhoudsbehandeling platinum sensitief recidief ovariumcarcinoom
- Alvleesklierkanker
- Prostate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide)
-
Pembrolizumab
- Treatment (monotherapy) of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin chemotherapy
- Head & Neck cancer
- Multipel Myeloma
- Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and subsequent-line
- Adjuvant melanoma stage III.Keytruda · Malignant melanoma - post-resection adjuvant therapy in high-risk patients
-
Pertuzumab
-
Pitolisant
-
Remedium
-
Ribociclib
-
Rucaparib (camsylate)
-
Sebelipase alfa
-
Sodium zirconium cyclosilicate
-
Tremelimumab
-
Veliparib
- Brain metastases from NSCLC
- Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel
- Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel
- Borstkanker
- Hersenkanker
-
Vemurafenib
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
-
Wondermiddel
-
-
Abemaciclib
-
Afamelanotide
-
Alicaforsen
-
Asfotase alfa
-
Atezolizumab
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Blaaskanker
- NSCLC, 2e behandeling
- Indication couldn't be found
- Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
-
Avelumab
-
Blinatumomab
-
Botulinum A toxin
- Chronic sialorrhoea in adults and children, associated with neurological conditions (Parkinson’s Disease (PD), stroke, traumatic brain injury (TBI), cerebral palsy (CP) (licence extension)
- Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI) (licence extension)
- Lower limb spasticity (LLS), post stroke (licence extension).
-
CTL019
-
Canakinumab
-
Cholic acid
-
Dupilumab
-
Durvalumab
- Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L monotherapy in PDL1-positive tumours or in combination with tremelimumab for PDL1-negative tumours.
- Non-small cell lung cancer (NSCLC) stage 4, PD-L1+, 1L
- Locally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum‑based regimen
-
Empagliflozin
-
Empagliflozin / linagliptin
-
Ibrutinib
-
Ipilimumab
-
Leuco-methylthioninium
-
Masitinib
-
Migalastat
-
Nivolumab
- Huidkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
-
Nivolumab
-
Obeticholic acid
-
Olaparib
- Breast cancer (HER2+, BCRA mutated; adjuv.)
- Tabletten ipv capsules voor onderhoudsbehandeling platinum sensitief recidief ovariumcarcinoom
- Alvleesklierkanker
- Prostate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide)
-
Pembrolizumab
- Treatment (monotherapy) of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin chemotherapy
- Head & Neck cancer
- Multipel Myeloma
- Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and subsequent-line
- Adjuvant melanoma stage III.Keytruda · Malignant melanoma - post-resection adjuvant therapy in high-risk patients
-
Pertuzumab
-
Pitolisant
-
Remedium
-
Ribociclib
-
Rucaparib (camsylate)
-
Sebelipase alfa
-
Sodium zirconium cyclosilicate
-
Tremelimumab
-
Veliparib
- Brain metastases from NSCLC
- Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel
- Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel
- Borstkanker
- Hersenkanker
-
Vemurafenib
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
-
Wondermiddel
-
-
Abemaciclib
-
Afamelanotide
-
Alicaforsen
-
Asfotase alfa
-
Atezolizumab
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Blaaskanker
- NSCLC, 2e behandeling
- Indication couldn't be found
- Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
-
Avelumab
-
Blinatumomab
-
Botulinum A toxin
- Chronic sialorrhoea in adults and children, associated with neurological conditions (Parkinson’s Disease (PD), stroke, traumatic brain injury (TBI), cerebral palsy (CP) (licence extension)
- Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI) (licence extension)
- Lower limb spasticity (LLS), post stroke (licence extension).
-
CTL019
-
Canakinumab
-
Cholic acid
-
Dupilumab
-
Durvalumab
- Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L monotherapy in PDL1-positive tumours or in combination with tremelimumab for PDL1-negative tumours.
- Non-small cell lung cancer (NSCLC) stage 4, PD-L1+, 1L
- Locally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum‑based regimen
-
Empagliflozin
-
Empagliflozin / linagliptin
-
Ibrutinib
-
Ipilimumab
-
Leuco-methylthioninium
-
Masitinib
-
Migalastat
-
Nivolumab
- Huidkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
-
Nivolumab
-
Obeticholic acid
-
Olaparib
- Breast cancer (HER2+, BCRA mutated; adjuv.)
- Tabletten ipv capsules voor onderhoudsbehandeling platinum sensitief recidief ovariumcarcinoom
- Alvleesklierkanker
- Prostate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide)
-
Pembrolizumab
- Treatment (monotherapy) of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin chemotherapy
- Head & Neck cancer
- Multipel Myeloma
- Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and subsequent-line
- Adjuvant melanoma stage III.Keytruda · Malignant melanoma - post-resection adjuvant therapy in high-risk patients
-
Pertuzumab
-
Pitolisant
-
Remedium
-
Ribociclib
-
Rucaparib (camsylate)
-
Sebelipase alfa
-
Sodium zirconium cyclosilicate
-
Tremelimumab
-
Veliparib
- Brain metastases from NSCLC
- Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel
- Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel
- Borstkanker
- Hersenkanker
-
Vemurafenib
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
-
Wondermiddel
-
-
Abemaciclib
-
Afamelanotide
-
Alicaforsen
-
Asfotase alfa
-
Atezolizumab
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Blaaskanker
- NSCLC, 2e behandeling
- Indication couldn't be found
- Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
-
Avelumab
-
Blinatumomab
-
Botulinum A toxin
- Chronic sialorrhoea in adults and children, associated with neurological conditions (Parkinson’s Disease (PD), stroke, traumatic brain injury (TBI), cerebral palsy (CP) (licence extension)
- Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI) (licence extension)
- Lower limb spasticity (LLS), post stroke (licence extension).
-
CTL019
-
Canakinumab
-
Cholic acid
-
Dupilumab
-
Durvalumab
- Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L monotherapy in PDL1-positive tumours or in combination with tremelimumab for PDL1-negative tumours.
- Non-small cell lung cancer (NSCLC) stage 4, PD-L1+, 1L
- Locally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum‑based regimen
-
Empagliflozin
-
Empagliflozin / linagliptin
-
Ibrutinib
-
Ipilimumab
-
Leuco-methylthioninium
-
Masitinib
-
Migalastat
-
Nivolumab
- Huidkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
-
Nivolumab
-
Obeticholic acid
-
Olaparib
- Breast cancer (HER2+, BCRA mutated; adjuv.)
- Tabletten ipv capsules voor onderhoudsbehandeling platinum sensitief recidief ovariumcarcinoom
- Alvleesklierkanker
- Prostate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide)
-
Pembrolizumab
- Treatment (monotherapy) of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin chemotherapy
- Head & Neck cancer
- Multipel Myeloma
- Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and subsequent-line
- Adjuvant melanoma stage III.Keytruda · Malignant melanoma - post-resection adjuvant therapy in high-risk patients
-
Pertuzumab
-
Pitolisant
-
Remedium
-
Ribociclib
-
Rucaparib (camsylate)
-
Sebelipase alfa
-
Sodium zirconium cyclosilicate
-
Tremelimumab
-
Veliparib
- Brain metastases from NSCLC
- Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel
- Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel
- Borstkanker
- Hersenkanker
-
Vemurafenib
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
-
Wondermiddel
-
-
Abemaciclib
-
Afamelanotide
-
Alicaforsen
-
Asfotase alfa
-
Atezolizumab
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Blaaskanker
- NSCLC, 2e behandeling
- Indication couldn't be found
- Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
-
Avelumab
-
Blinatumomab
-
Botulinum A toxin
- Chronic sialorrhoea in adults and children, associated with neurological conditions (Parkinson’s Disease (PD), stroke, traumatic brain injury (TBI), cerebral palsy (CP) (licence extension)
- Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI) (licence extension)
- Lower limb spasticity (LLS), post stroke (licence extension).
-
CTL019
-
Canakinumab
-
Cholic acid
-
Dupilumab
-
Durvalumab
- Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L monotherapy in PDL1-positive tumours or in combination with tremelimumab for PDL1-negative tumours.
- Non-small cell lung cancer (NSCLC) stage 4, PD-L1+, 1L
- Locally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum‑based regimen
-
Empagliflozin
-
Empagliflozin / linagliptin
-
Ibrutinib
-
Ipilimumab
-
Leuco-methylthioninium
-
Masitinib
-
Migalastat
-
Nivolumab
- Huidkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
-
Nivolumab
-
Obeticholic acid
-
Olaparib
- Breast cancer (HER2+, BCRA mutated; adjuv.)
- Tabletten ipv capsules voor onderhoudsbehandeling platinum sensitief recidief ovariumcarcinoom
- Alvleesklierkanker
- Prostate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide)
-
Pembrolizumab
- Treatment (monotherapy) of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin chemotherapy
- Head & Neck cancer
- Multipel Myeloma
- Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and subsequent-line
- Adjuvant melanoma stage III.Keytruda · Malignant melanoma - post-resection adjuvant therapy in high-risk patients
-
Pertuzumab
-
Pitolisant
-
Remedium
-
Ribociclib
-
Rucaparib (camsylate)
-
Sebelipase alfa
-
Sodium zirconium cyclosilicate
-
Tremelimumab
-
Veliparib
- Brain metastases from NSCLC
- Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel
- Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel
- Borstkanker
- Hersenkanker
-
Vemurafenib
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
-
Wondermiddel
-
-
Abemaciclib
-
Afamelanotide
-
Alicaforsen
-
Asfotase alfa
-
Atezolizumab
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Blaaskanker
- NSCLC, 2e behandeling
- Indication couldn't be found
- Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
-
Avelumab
-
Blinatumomab
-
Botulinum A toxin
- Chronic sialorrhoea in adults and children, associated with neurological conditions (Parkinson’s Disease (PD), stroke, traumatic brain injury (TBI), cerebral palsy (CP) (licence extension)
- Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI) (licence extension)
- Lower limb spasticity (LLS), post stroke (licence extension).
-
CTL019
-
Canakinumab
-
Cholic acid
-
Dupilumab
-
Durvalumab
- Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L monotherapy in PDL1-positive tumours or in combination with tremelimumab for PDL1-negative tumours.
- Non-small cell lung cancer (NSCLC) stage 4, PD-L1+, 1L
- Locally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum‑based regimen
-
Empagliflozin
-
Empagliflozin / linagliptin
-
Ibrutinib
-
Ipilimumab
-
Leuco-methylthioninium
-
Masitinib
-
Migalastat
-
Nivolumab
- Huidkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
-
Nivolumab
-
Obeticholic acid
-
Olaparib
- Breast cancer (HER2+, BCRA mutated; adjuv.)
- Tabletten ipv capsules voor onderhoudsbehandeling platinum sensitief recidief ovariumcarcinoom
- Alvleesklierkanker
- Prostate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide)
-
Pembrolizumab
- Treatment (monotherapy) of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin chemotherapy
- Head & Neck cancer
- Multipel Myeloma
- Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and subsequent-line
- Adjuvant melanoma stage III.Keytruda · Malignant melanoma - post-resection adjuvant therapy in high-risk patients
-
Pertuzumab
-
Pitolisant
-
Remedium
-
Ribociclib
-
Rucaparib (camsylate)
-
Sebelipase alfa
-
Sodium zirconium cyclosilicate
-
Tremelimumab
-
Veliparib
- Brain metastases from NSCLC
- Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel
- Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel
- Borstkanker
- Hersenkanker
-
Vemurafenib
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
-
Wondermiddel
-
-
Abemaciclib
-
Afamelanotide
-
Alicaforsen
-
Asfotase alfa
-
Atezolizumab
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Blaaskanker
- NSCLC, 2e behandeling
- Indication couldn't be found
- Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
-
Avelumab
-
Blinatumomab
-
Botulinum A toxin
- Chronic sialorrhoea in adults and children, associated with neurological conditions (Parkinson’s Disease (PD), stroke, traumatic brain injury (TBI), cerebral palsy (CP) (licence extension)
- Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI) (licence extension)
- Lower limb spasticity (LLS), post stroke (licence extension).
-
CTL019
-
Canakinumab
-
Cholic acid
-
Dupilumab
-
Durvalumab
- Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L monotherapy in PDL1-positive tumours or in combination with tremelimumab for PDL1-negative tumours.
- Non-small cell lung cancer (NSCLC) stage 4, PD-L1+, 1L
- Locally advanced or metastatic urothelial carcinoma (UC) whose disease has progressed during or after one standard platinum‑based regimen
-
Empagliflozin
-
Empagliflozin / linagliptin
-
Ibrutinib
-
Ipilimumab
-
Leuco-methylthioninium
-
Masitinib
-
Migalastat
-
Nivolumab
- Huidkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Longkanker
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
-
Nivolumab
-
Obeticholic acid
-
Olaparib
- Breast cancer (HER2+, BCRA mutated; adjuv.)
- Tabletten ipv capsules voor onderhoudsbehandeling platinum sensitief recidief ovariumcarcinoom
- Alvleesklierkanker
- Prostate cancer - monotherapy for BRCA 1/2 or ATM gene-mutated metastatic castration resistant prostate cancer (mCRPC) in patients who have received a prior taxane-based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide)
-
Pembrolizumab
- Treatment (monotherapy) of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin chemotherapy
- Head & Neck cancer
- Multipel Myeloma
- Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma - second- and subsequent-line
- Adjuvant melanoma stage III.Keytruda · Malignant melanoma - post-resection adjuvant therapy in high-risk patients
-
Pertuzumab
-
Pitolisant
-
Remedium
-
Ribociclib
-
Rucaparib (camsylate)
-
Sebelipase alfa
-
Sodium zirconium cyclosilicate
-
Tremelimumab
-
Veliparib
- Brain metastases from NSCLC
- Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel
- Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel
- Borstkanker
- Hersenkanker
-
Vemurafenib
- Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab
- Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
-
Wondermiddel